Investors & Partners at 5AM Ventures

John Diekman

Founding and Managing Partner, 5AM Ventures

John Diekman is Founding and Managing Partner at 5AM Ventures, a prominent venture capital firm focused on early-stage investments in biotech and digital health. In his leadership role, Diekman directs the firm's investment strategy and portfolio development across these high-impact sectors. With deep expertise in life sciences and healthcare technology, he identifies and supports innovative companies positioned to transform patient care and advance scientific discovery. As a founding partner, Diekman has been instrumental in establishing 5AM Ventures' reputation as a sophisticated investor in the biotech and digital health spaces, working closely with entrepreneurs to scale transformative healthcare solutions from concept through commercialization.

Kush M Parmar

Managing Partner, 5AM Ventures

Kush Parmar brings a cross-border perspective to life sciences investing, having been born in New Jersey, raised in India, and returned to the U.S. for his medical training, which he now applies to building globally relevant biotech companies including India-focused initiatives. Unlike typical VCs, he consistently takes hands-on company-building leadership roles beyond board seats, serving as co-founder, chair, or senior executive at multiple portfolio companies while leveraging his M.D./Ph.D. training from Harvard to evaluate technical science and work directly with founders on translational strategy.

Scott Rocklage

Founding Partner, 5AM Ventures

Scott Rocklage is a Founding Partner at 5AM Ventures, a leading venture capital firm specializing in biotech and digital health investments. With deep expertise in life sciences and healthcare innovation, Rocklage focuses on identifying and supporting transformative companies at the intersection of biology and technology. As a founding member of 5AM Ventures, he plays a key role in sourcing, evaluating, and scaling portfolio companies that address critical healthcare challenges. His investment thesis emphasizes breakthrough scientific innovations with strong commercial potential and the ability to meaningfully impact patient outcomes. Rocklage brings a strategic perspective to early and growth-stage investments in the biotech and digital health sectors, working closely with entrepreneurs to build category-defining companies.